Cysticercosis
7
1
1
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Natural History of Treated Neurocysticercosis and Long-Term Outcomes
Two Cases of Pulmonary Cysticercosis Manifesting as Pleural Effusion: Case Report and Literature Review
Digital Health Promotion in Iringa, Tanzania
EFECAB: Improving Pig Management to Prevent Epilepsy in Burkina Faso
Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis
Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis
Taenia Solium Control Case Study in Zambia